Laboratory of Reproductive Biology, The Juliane Marie Center for Women, Children and Reproduction, University Hospital of Copenhagen, Copenhagen, Denmark.
The Fertility Clinic, Department of Gynecology and Obstetrics, Zealand University Hospital, Køge, Denmark.
Acta Obstet Gynecol Scand. 2019 May;98(5):616-624. doi: 10.1111/aogs.13575. Epub 2019 Mar 7.
Young women with a cancer diagnosis often have very little time to decide whether or not to commence fertility-preserving strategies before initiating potentially sterilizing cancer treatment. Minimizing the interval from opting for fertility preservation to completion of the procedure will reduce the potential risk of delaying cancer treatment. In the current study, we have evaluated the period of time from referral to ovarian tissue cryopreservation (OTC) to actual freezing of the tissue in a cohort of Danish women.
The study population comprised 277 consecutive patients with both malignant and nonmalignant diseases referred for OTC from four centers in the Danish network. Statistical analysis was conducted to analyze the impact of age, diagnosis, and referring center on the time from OTC-referral to OTC. A literature search for "random start" protocols for controlled ovarian stimulation (COS) for fertility preservation in cancer patients was performed.
The time from OTC-referral to OTC was significantly influenced by diagnosis, age, and referring center. Women with malignant diseases other than breast cancer, such as sarcomas, pelvic cancers, and hematological cancers, experienced a significantly shorter interval to OTC (5 days) than women with breast cancer (7 days) and nonmalignant diseases including systemic, ovarian, and hereditary conditions (13-17.5 days). Women over the age of 30 years experienced a significantly longer time to OTC (P < 0.03), and the diagnosis determined the length of the interval (P < 0.001). According to the literature, fertility preservation by oocyte vitrification requires 13-14 days, as the average time for 1 round of COS was 11 days and oocyte collection can be performed 2 days later.
It is in the interest of both cancer patients and clinicians to perform fertility preservation as quickly and safely as possible. In a Danish setting, OTC provides a short interval of around 6 days from the patient choosing this option to completion of the procedure. This is considerably less time than what is needed to perform COS and oocyte vitrification, and therefore OTC might be considered the preferred choice of fertility preservation when urgency is needed.
年轻女性被诊断患有癌症后,通常只有很短的时间来决定是否在开始可能会导致绝育的癌症治疗之前开始进行生育力保存策略。尽量缩短选择生育力保存到完成该程序的时间间隔,可以降低延迟癌症治疗的潜在风险。在本研究中,我们评估了丹麦女性队列中从卵巢组织冷冻(OTC)转诊到实际冷冻组织的时间间隔。
研究人群包括来自丹麦网络四个中心的 277 名患有恶性和非恶性疾病的连续患者,这些患者都被转诊接受 OTC。进行了统计学分析,以分析年龄、诊断和转诊中心对 OTC 转诊到 OTC 的时间的影响。针对癌症患者生育力保存的控制性卵巢刺激(COS)的“随机开始”方案进行了文献检索。
从 OTC 转诊到 OTC 的时间明显受到诊断、年龄和转诊中心的影响。患有除乳腺癌以外的恶性疾病(如肉瘤、盆腔癌和血液癌)的女性比患有乳腺癌(7 天)和非恶性疾病(包括系统性、卵巢性和遗传性疾病)的女性到 OTC 的时间间隔明显缩短(5 天)。年龄超过 30 岁的女性到 OTC 的时间明显延长(P<0.03),且诊断决定了间隔的长度(P<0.001)。根据文献,卵母细胞玻璃化需要 13-14 天的时间来进行生育力保存,因为 1 轮 COS 的平均时间为 11 天,并且可以在 2 天后进行卵母细胞采集。
尽快且安全地进行生育力保存符合癌症患者和临床医生的利益。在丹麦的环境下,OTC 从患者选择该选项到完成该程序的时间间隔约为 6 天。这比进行 COS 和卵母细胞玻璃化所需的时间要短得多,因此,当需要紧急情况时,OTC 可能被认为是生育力保存的首选选择。